Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model
作者:Ilaria Paterni、Simone Bertini、Carlotta Granchi、Tiziano Tuccinardi、Marco Macchia、Adriano Martinelli、Isabella Caligiuri、Giuseppe Toffoli、Flavio Rizzolio、Kathryn E. Carlson、Benita S. Katzenellenbogen、John A. Katzenellenbogen、Filippo Minutolo
DOI:10.1021/jm501829f
日期:2015.2.12
Estrogen receptor β (ERβ) selective agonists are considered potential therapeutic agents for a variety of pathological conditions, including several types of cancer. Their development is particularly challenging, since differences in the ligand binding cavities of the two ER subtypes α and β are minimal. We have carried out a rational design of new salicylketoxime derivatives which display unprecedentedly
雌激素受体β(ERβ)选择性激动剂被认为是各种病理状况(包括几种癌症)的潜在治疗剂。它们的发展特别具有挑战性,因为两种ER亚型α和β的配体结合腔差异很小。我们已经进行了新的水杨基酮肟衍生物的合理设计,该衍生物在结合亲和力和基于细胞的功能测定中均显示出对此类化合物而言前所未有的高水平的ERβ选择性。内源性基因表达测定法用于进一步表征这些化合物的药理作用。最后,发现这些ERβ选择性激动剂在体外抑制神经胶质瘤细胞系的增殖。最重要的是,